Teva says real-world data show UZEDY cuts schizophrenia patients’ monthly healthcare costs by USD 1,036.70 vs PP1m
TEVA•Real-world data on UZEDY presented at Psych Congress
Teva disclosed new real-world studies on UZEDY at Psych Congress, with results already presented during the Sept. 15-19, 2026 meeting.
- Data in schizophrenia showed UZEDY kept more patients on therapy than competing long-acting injectables, supporting stronger treatment continuity.
- Patients on UZEDY recorded fewer emergency-care events, lowering healthcare utilization versus key long-acting injectable comparators.
- Teva also cited lower direct healthcare spending for UZEDY patients, translating into more than USD 1,000 per patient per month savings.
- In bipolar I maintenance, patients switching from oral antipsychotics to UZEDY had fewer treatment failures than those switching to another oral option.
